Form4insider filings, from the source

SEC Form 5 · accession 0001511164-17-000414

INVO Bioscience, Inc. · IVOB

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Claude Ranoux
Officer — President · Director · 10% Owner
Period of report
Dec 31, 2010
Accepted (ET)
Jul 26, 2017 · 12:21 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001417926

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
INVO Bioscience Common Stock (Free trading)Dec 29, 2010D10,000$0.036D25,883,367D
INVO Bioscience Common Stock (Free trading)Dec 29, 2010D12,000$0.038D25,871,367D
INVO Bioscience Common Stock (Free trading)Dec 30, 2010D7,500$0.038D25,863,867D
INVO Bioscience Common Stock (Free trading)Dec 31, 2010D20,000$0.038D25,843,867D
INVO Bioscience Common Stock (Free trading)Dec 31, 2010D10,000$0.04D25,833,867D

Table II — derivative securities

No Table II lines on this filing.

Remarks

During year 2010, I traded my securities on the public market using Morgan Stanley Smith Barney, as my agent, my account number is 486-175757-0-161. I used Morgan Stanley, until 03/29/2012; financial difficulties did not allow INVO Bioscience to pay for the financial audits. From March 29, 2012 until 2017, the stock of INVO Bioscience was traded in the Pink Sheet. On December 27, 2010, I acquired 650,000 restricted securities. The total of restricted shares was 24,661,473 (2008) + 650,000 = 25,311,473 restricted securities. In 2010, I sold 307,606 free trading shares. On 12/31/2010 the total of free trading shares left was 830,000 (2009) - 307,606 = 522,394 free trading shares. In December 31, 2010, the total of securities I owned was 25,491,473 (2009) + 650,000 - 307,606 = 25,833,867 shares.